Dow Jones

40,211.72

0.53%

Regístrate para interactuar en nuestros foros activos para discutir con inversores de ideas afines.

Regístrate

XLRN

Acceleron Pharma (XLRN)

Acceleron Pharma Inc

Fecha:

Regulatory News

Text Search:

Ordernar por:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:XLRN

<< Anterior 1 2 3 4 5 6 7 8 9 10 11 Próxima >

Fecha	Hora	Fuente	Título	Símbolo	Compañía
09/12/2019	06:30	Business Wire	Acceleron Appoints Jay T. Backstrom, M.D., M.P.H., to Newly Created Role as Head of Research and Development	NASDAQ:XLRN	Acceleron Pharma Inc
06/12/2019	16:27	Edgar (US Regulatory)	Current Report Filing (8-k)	NASDAQ:XLRN	Acceleron Pharma Inc
06/12/2019	11:45	Dow Jones News	Bristol-Myers, Acceleron: FDA Drops Planned Panel Review of Reblozyl	NASDAQ:XLRN	Acceleron Pharma Inc
06/12/2019	11:05	Business Wire	Bristol-Myers Squibb and Acceleron Pharma Provide Update on FDA Advisory Committee for Reblozyl® (luspatercept-aamt)	NASDAQ:XLRN	Acceleron Pharma Inc
06/12/2019	07:00	Business Wire	Acceleron Appoints Global Innovation and Drug Development Executive Kemal Malik, MB BS, to its Board of Directors	NASDAQ:XLRN	Acceleron Pharma Inc
04/12/2019	15:01	Business Wire	Acceleron Named a “Most Honored” Company in Institutional Investor 2020 “All-America Executive Team” Rankings	NASDAQ:XLRN	Acceleron Pharma Inc
03/12/2019	07:35	Dow Jones News	Bristol-Myers, Acceleron: FDA Panel to Review Reblozyl in Myelodysplastic Syndromes	NASDAQ:XLRN	Acceleron Pharma Inc
03/12/2019	06:38	Business Wire	Bristol-Myers Squibb & Acceleron Pharma Announce FDA Advisory Committee Will Review Reblozyl® (luspatercept-aamt) for Use in...	NASDAQ:XLRN	Acceleron Pharma Inc
02/12/2019	06:00	Business Wire	Acceleron to Host Conference Call and Webcast to Review Data Presented at the 61st American Society of Hematology Annual Meet...	NASDAQ:XLRN	Acceleron Pharma Inc
12/11/2019	09:16	Edgar (US Regulatory)	Amended Statement of Ownership (sc 13g/a)	NASDAQ:XLRN	Acceleron Pharma Inc
08/11/2019	12:30	Dow Jones News	Acceleron Pharma Shares Gain Ground After FDA Approves Reblozyl	NASDAQ:XLRN	Acceleron Pharma Inc
08/11/2019	12:20	Dow Jones News	FDA Approves Celgene's and Acceleron's Reblozyl to Treat Rare Blood Disorder	NASDAQ:XLRN	Acceleron Pharma Inc
08/11/2019	11:33	Business Wire	FDA Approves REBLOZYL® (luspatercept-aamt) for the Treatment of Anemia in Adults With Beta Thalassemia Who Require Regular R...	NASDAQ:XLRN	Acceleron Pharma Inc
06/11/2019	08:05	Business Wire	Acceleron Announces Luspatercept Presentations at the 61st American Society of Hematology Annual Meeting	NASDAQ:XLRN	Acceleron Pharma Inc
06/11/2019	06:59	Edgar (US Regulatory)	Quarterly Report (10-q)	NASDAQ:XLRN	Acceleron Pharma Inc
06/11/2019	06:53	Business Wire	Acceleron Reports Third Quarter 2019 Operating and Financial Results	NASDAQ:XLRN	Acceleron Pharma Inc
29/10/2019	06:00	Business Wire	Acceleron to Webcast Third Quarter 2019 Operating and Financial Results on November 6, 2019	NASDAQ:XLRN	Acceleron Pharma Inc
16/09/2019	15:30	Business Wire	Acceleron Announces Topline Results from the Phase 2 Trial of ACE-083 in Patients with Facioscapulohumeral Muscular Dystrophy	NASDAQ:XLRN	Acceleron Pharma Inc
09/09/2019	06:00	Business Wire	Acceleron Receives FDA Orphan Drug Designation for Sotatercept in Pulmonary Arterial Hypertension	NASDAQ:XLRN	Acceleron Pharma Inc
12/08/2019	15:19	Edgar (US Regulatory)	Statement of Changes in Beneficial Ownership (4)	NASDAQ:XLRN	Acceleron Pharma Inc
05/08/2019	15:05	Business Wire	Acceleron Reports Second Quarter 2019 Operating and Financial Results	NASDAQ:XLRN	Acceleron Pharma Inc
24/07/2019	06:00	Business Wire	Acceleron to Webcast Second Quarter 2019 Operating and Financial Results on August 5, 2019	NASDAQ:XLRN	Acceleron Pharma Inc
05/07/2019	08:54	Edgar (US Regulatory)	Confidential Treatment Order (ct Order)	NASDAQ:XLRN	Acceleron Pharma Inc
26/06/2019	06:35	Business Wire	Acceleron Completes Target Enrollment in the PULSAR Phase 2 Trial of Sotatercept in Pulmonary Arterial Hypertension	NASDAQ:XLRN	Acceleron Pharma Inc
10/06/2019	06:00	Business Wire	Acceleron Announces Retirement of Director and Co-Founder Tom Maniatis	NASDAQ:XLRN	Acceleron Pharma Inc
07/06/2019	15:39	Edgar (US Regulatory)	Initial Statement of Beneficial Ownership (3)	NASDAQ:XLRN	Acceleron Pharma Inc
04/06/2019	07:24	Dow Jones News	FDA Accepts Celgene, Acceleron BLA for Anemia Drug Luspatercept	NASDAQ:XLRN	Acceleron Pharma Inc
04/06/2019	06:30	Business Wire	Celgene Corp. & Acceleron Pharma Announce U.S. FDA Accepts Luspatercept Biologics License Application in Myelodysplastic Synd...	NASDAQ:XLRN	Acceleron Pharma Inc
14/05/2019	06:00	Business Wire	Acceleron to Present at the UBS Global Healthcare Conference	NASDAQ:XLRN	Acceleron Pharma Inc
09/05/2019	15:05	Business Wire	Acceleron Reports First Quarter 2019 Operating and Financial Results	NASDAQ:XLRN	Acceleron Pharma Inc